
Opinion|Videos|September 30, 2024
Perspectives on Latest Therapies: Faricimab and Aflibercept 8mg
Author(s)Nikolas London, MD, FACS
Fact checked by: Nikolas London, MD, FACS
Dr. London discusses the implications of faricimab and aflibercept 8 mg in treating retinal diseases, highlighting their mechanisms, efficacy data, and potential to enhance patient outcomes in conditions like wet age-related macular degeneration.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
NCX 470 gains positive regulatory feedback in China ahead of US NDA submission
2
DSLT for glaucoma and ocular hypertension: Real-world outcomes in 218 eyes
3
FDA accepts Outlook Therapeutics' resubmitted BLA for ONS-5010 (LYTENAVA)
4
Tinlarebant NDA submission completed for Stargardt disease type 1, targeting first approved therapy
5

















